Ras like without CAAX 2Genealiases: RIBA · RIN · ROC2
Q-omics provides the consensus-scored RIT2 profile across patient tissues and cancer cell-line models. RIT2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RIT2 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, RIT2 RNA expression shows 9,273 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, COAD, and TGCT as cancer lineages where RIT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIT2 survival associations across molecular data types. RIT2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIT2 RNA expression–survival associations across cancer types. High RIT2 expression shows unfavorable associations in LUAD, STAD, THCA and ESCA, but favorable associations in READ and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .012). Together, the overview and detailed table identify LUAD as the clearest survival context for RIT2 RNA expression.
This table summarizes RIT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RIT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIT2 shows lower tumor expression in COAD, THCA, LIHC, READ and KICH and higher tumor expression in BRCA. The COAD box plot shows higher RIT2 RNA expression in normal versus tumor tissue (log2 FC = −0.153, t-test p < 0.001).
This table shows molecular features associated with RIT2 in patient tissues and cancer cell lines. In patient samples, RIT2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RIT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
